Page 10 - Numinus Bioscience News Today

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology Numinus Wellness Inc. a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal third quarter results ended May 31, 2021 . In the third quarter, Numinus maintained a healthy cash position, achieved key milestones in its lab and proprietary portfolio, expanded the clinic ...

The initial trial would focus on dosage before expanding into psilocybin treatments for a variety of health conditions. “This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations,” said Optimi chairman of the board JJ Wilson. The information package included the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from psilocybe mush...

Sairiyo Therapeutics Inc., for the use of DMT in organ transplantations. When patients undergo an organ transplant, theres a high risk of ischemia-reperfusion injury, a type of injury that can occur when blood rapidly returns to the organ after being restricted by a long period. This can lead to the organ being rejected by the body, as well as other injuries to the patient. Preclinical models of kidney transplantation showed that DMT can be used to mitigate injury caused by ischemia-reperfusion...

Numinus Wellness ends 2Q with C$28.5M after closing Mindspace Wellbeing acquisition Subsequent to the quarter-end, Numinus completed a $40.25 million financing and raised an additional $1.5 million from warrant exercises, putting its current cash balance at around $65 million The Vancouver-based firm is the first Canadian public company to successfully legally extract psilocybe mushrooms, a feat it achieved during 2Q Numinus Wellness Inc (CVE:NUMI) (OTCMKTS:LKYSF) (FRA:LR23)  saw i...

Numinus’ new Phase I clinical trial, to be conducted in partnership with  KGK Science, will test out the company’s own naturally derived psilocybin formulation on human subjects. The trial will enroll 14 healthy volunteers and will assess the safety and psychoactive properties of a Psilocybe mushroom formulation extracted at the Numinus Bioscience lab in British Columbia. The company holds a license to cultivate and extract magic mushrooms in Canada. As opposed to most psilocybin clinical...

NA Proactive news snapshot: PsyBio Therapeutics, Numinus Wellness, Arizona Silver Exploration, Loop Insights, Canada Silver Cobalt Works … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive PsyBio Therapeutics Corp (CVE:PSYB) (FRA:PSYB) announced that it has amended its master-sponsored agreement with Miami University based in Oxford, Ohio for the continued advancement of its neuropsychiatr...

NA Proactive news snapshot: FPX Nickel, ESE Entertainment, Fortitude Gold, Progressive Planet Solutions, Safe-T Group UPDATE … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive FPX Nickel Corp (CVE:FPX) has announced the initiation of a metallurgical pilot test program to support development of its Baptiste nickel project in central British Columbia, the largest and most comprehensive progr...

NA Proactive news snapshot: Bragg Gaming, Lexaria Bioscience, FPX Nickel, ESE Entertainment, Fortitude Gold UPDATE … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Haywood Capital Markets is initiating coverage of Bragg Gaming Group Inc (TSE:BRAG) (OTCMKTS:BRGGF) (FRA:SL4A) with a Buy rating and a $3 price target. In its note, Haywood cited three key catalysts helping the company -- a po...

Why Canada is Becoming a Hub for Psychedelics Research and Development FN Media Group Presents Microsmallcap.com Market Commentary News provided by Share this article Share this article NEW YORK, March 17, 2021 /PRNewswire/ -- Canada has become home to some of the most important research and development happening today in the mental health and wellness space. Psychedelic therapy emerged as a breakthrough mental health treatment, and Canadian companies are leading the way in developing psychedel...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN ...